DAFTAR PUSTAKA

Aisen, P.S., Davis,K.L, Berg, J.D.,Schafer, K., Campbell, K., Thomas, R.G., et al.
(2000). A randomized controlled trial of prednisone in Alzheimers disease.
Alzheirmers Disease Cooperative Study. Neurology, 54, 588-93.
Alvir, J.M., Lieberman, J.A., Safferman, A.Z., Schwimmer, J.L., and Schaaf, J.A.
(1993). Clozapine-induced agranulocytosis. Incidence and risk factors in the United
States. New England Journal of Medicine, 329, 162-7.
Amenta, F., Zaccheo, D., and Collier, W.L. (1991). Neurotransmitter, neuroreceptors
and aging. Mechanics of Ageing and Development, 61, 249-73.
American Psychiatry Association. (1990). Benzodiazepine dependence, toxicity and
abuse. America Psychiatry Association, Washington, DC.
American Psychiatry Association. (1997). Practice guideline for the treatment of the
patients with Alzheimers disease and other dementias of late life. American
Journal of Psychiatry, 154(Suppl.) 1-39.
Anderson, G., Vestergaard, L., and Lauritzen, L. (1994). Effective treatment of
poststroke depression with the selective serotonin reuptake inhibitor citalopram.
Stroke, 25, 1099-104.
Andersen, J., Aabro, E., Gulmann, N., Hjelmsted, A., and Pedersen, H.E. (1980).
Antidepressive treatment in Parkinsons disease. A controlled trial of the effect on
notriptyline in Parkinsons disease with L-DOPA. Acta Neurologica Scandinavica,
62, 210-19.
Antony, M.M. and Swinson, R.P. (1996). Anxiety disorders and their treatment: a
critical review of the evidence-based literature. Health Canada, Ottawa.
Baldessarini, R.j., Tondo, L., Suppes, T., Faedda, G.L., and Tohen, M. (1996).
Pharmacological treatment of bipolar disorder throughout the life city. In Mood
disorders across the life span (ed. K.I. Shulman, M. Tohen, and S.P. Kutcher), pp.
299-338. Wiley, New York.
Barbhaiya, R.H., Buch, A.B., and Greene, D.S. (1996). A study of the effect of age and
genderon the pharmacokinetics of nefazodone after single and multiple doses.
Journal of Clinical Psychopharmacology, 16,19-25.
Breitbat, W., Marotta, R., Platt, M.M., Weisman, H., Derevenco, M., Grau C., et al.
(1996). A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the
treatment of delirioum in hospitalized AIDS patients. American Journal of
Psychiatry, 153, 231-7.
Burke, W.J., Roccaforte, W.H., Wengel, S.P., Bayer, B.L., Ranno, A.E., and
Willcockson, N.K. (1993). L-deprenyl in the treatment of mild dementia of the
Alzheimer type: result of a 15-month trial. Journal of the America Geriatrics
Society, 41, 1219-25.

Cates, M. and Poers, R. (1998). Concominant rash and blood dyscrasias in geriatric
psychiatry patients treated with carbamazepine. Annals of Pharmacotherapy, 32,
884-7.
Catterson, M.L., Preskorn, S.H., and Martin, R.L. (1997). Pharmacodynamics and
pharmacokinetic considerations in geriatric psychopharmacology. Psychiatric
Clinics of North America, 20, 205-18.
Cooney, C., Mortimer, A., Smith, A., Newton, K., and Wrigley, M. (1996).
Carbamazapine use in aggressive behavior associated with senile dementia.
International Journal of Geriatric Psychiatry, 11, 901-5.
Crewe, H.K., Lennard, M.S. Tucker, G.T., Wood, F.R., and Haddock, R.E. (1992). The
effect of selective serotin re-uptake inhibitors on cytochrome P450 2D6 (CYP2D6)
activity in human liver microsomes. British Journal of Clinical Pharmacology, 24,
262-5.
Dhelin, O., Hedenrud, B., Jansson, P., and Norgard J. (1985). A double-blind
comparison of alaprocate and placebo in the treatment of patients with senile
dementia. Acta Psychiatrica Scandinavica, 71, 190-6.
Devanand, D.P., Marder. K., Michaels, K.S., Sackeim, H.A., Bell, K., Sullivan, M.A., et
al. (1998). A randomized, placebo-controlled dose-comparison trial of haloperidol
for psychosis and disruptive behaviors in Alzheimers disease. American Journal of
Psychiatry, 155, 1512-20.
Eastham, J.H., Jeste, D.V. and Young R.C. (1998). Assessment and treatment of bipolar
disorder in the elderly. Drugs and Aging, 12, 205-24.
Eichelbaum, M. and Gross, A.S. (1990). The genetic polymorphism of
debrisoquine/sparteine metabolism clinical aspects. Pharmacology and
Therapeutics, 46, 377-94.
Emptage, R.E. and Semla, T.P. (1996). Depression in the medically ill elderly: a focus
on methylphenidate. Annals of Pharmacotherapy, 30, 151-7.
Evans, M. Hammod, M., Wilson, K., Lye, M., and Copeland, J. (1997). Placebocontrolled treatment trial of depression in the elderly physically ill patients.
International Journal of Geriatirc Psychiatry, 12, 817-24.
Feighner, J.P. (1994). The role of venlafaxine in rational antidepressant therapy. Journal
of Clinical Psychiatry, 55 (9 Suppl. A), 62-8.
Finkel, S.I. Lyons, J.S., Anderson, R.L., Sherrell, K. Davis, J., Cohen-Mansfield, J., et
al. (1995). A randomized, placebo-controlled trial of thiothixene in agitated,
demented nursing home patients. International Journal of Geriatric Psychiatry, 10,
129-36.
Finlay-Jones, R. and Parker, G. (1993). A consensus conference on Psychotic
depression. Australian and New Zealand Journal of Psychiatry, 27, 581-9.
Flint, A.J. (1993). Ageing as a risk factor for lithium neurotoxicity at therapeutic serum
levels. British Journal of Psychiatry, 163, 555-6.

Flint, A.J. (1994). Epidemiology and comorbidity of anxiety disorders in the elderly.
American Journal of Psychiatry, 151, 640-9.
Flint, A.J. (1995). Argumentation strategies in geriatric depression, International
Journal of Geriatric Psychiatry, 10, 137-46
Flint, A.J. (1998b). Management of anxiety in late life. Journal of Geriatric Psychiatry
and Neurology, 11, 194-200
Flint, A.J. and Rifat, S.L. (1998). The treatment of psychotic depression in later life: a
comparison of pharmacotheraphy and ECT. International Journal of Geriatric
Psychiatry, 13, 23-8
Flint, A.J. and Van Reekum, R. (1998). The pharmacologic treatment of Alzheirmers
disease: a guide for the general psychiatrist. Canadian Journal of Psychiatry, 43,
689-97.
Flint, A.J., Crosby, J., and Genik, J.L. (1996). Recurrent hyponatremia associated with
fluoxetine and paroxetine, American Journal of Psychiatrym, 153, 134.
Freeman, M.P. and Stoll, A.L. (1998). Mood stabilizer combinations: a review of safety
and efficacy. American Journal of Psychiatry, 155, 12-21
Galynker, I., Ieronimo, C., Minner, C., Rosenblum, J., Vilkas, N., and Rosenthal, R.
(1997). Methylphrnidate treatment of negative symptoms in patients with dementia.
Journal of Neuropsychiatry and Clinical Neurosciences, 9, 231-9.
Georgotas, A., McCue, R.E., Hapworth, W.E, Friedmean, E., Kim, O.M. Welkowitz, J.,
et al. (1986). Comparative efficacy and safety of MAOIs versus TCAs in treating
depression in the elderly. Biological Psychiatry, 21, 1155 66.
Goldberg, R.J. (1997). Antidepressant use in the elderly. Current status of nefazodone,
venlazadone, venlafaxine, and moclobemide. Drugs and Aging. 11, 119-3
Goodnick, P.J., (1994). Pharmacokinetic optimization of therapy with newer
antidepressant. Clinical pharmacokinetics, 27, 307-30
Greenberg, R.M. (1997). ECT in the elderly, New Direction for Mental Health Services,
76, 85-96
Grimsley, S.R. and Jann, M.W. (1992). Paraxotine, sertraline and fluxovamine: new
selective serotin reuptake inhibitors. Clinical Pharmacy, 11, 930-57
Harvey, A.T. and Preskorn, S.H. (1996). Cytochrome P450 enzymes: interpretation of
their interactions with selective serotonin reuptake inhibitors. Part II. Journal of
Psychopharmocology, 16, 345-55
Hauser, R.A. and Zesiewich, T.A. (1997). Sertraline for the treatment of depression in
Parkinsons disease. Movement Disorders, 12, 756-9
Henderson, V.W., Paganini-Hill, A., Miller, B.L., Elble, R.J., Reyes, P.F., Shoupe, D., et
al. (2000). Estrogen for Alzheimers disease in women: randomized, double-blind,
placebo-controlled trial. Neurology, 54, 295-301

Hindmarch, I. and Kerr, J.S. (1994). Effects of paroxetine on cognitive function in

depressed patients, volunteers and elderly volunteers. Medical Science Research,
22, 669-70
HIndmarch, I., Shillingford, J., and Shillingford, C. (1990). The effects of sertraline of
psychomotor performance in elderly volunteers. Journal of Clinical Psychiatry, 51
(12 Suppl. B), 34-6
Hirschfeld, R.M. and Markham, A. (1999). Mirtazapine. A review of its use in major
depression. Drugs. 57, 607-31
Jacobson, S.A, (1997). Delirium in the elderly. Psychiatric Clinics of North America,
20, 91-110
Jeste, D.V., Lacro, J.P., Beiley, A., Rockwell, E., Harris, M.J., and Caligiuri M.P. (1999).
Lower incidence of tardive dyskinesia with risperidone compared with haloperidol
in older patients. Journal of the American Geriatrics Society, 47, 716-19.
Kane, J.M., Woermer, M., and Lieberman, J. (1988). Tradive dyskinesia: prevalence,
incidence and risk factors, Journal of Clinical Psychopharmacology, 8(4 Suppl.),
52S-56S.
Katz, I.R., Simpson, G.M., Curlik, S.M., Parmelee, P.A., and Muhly, C. (1990).
Pharmacologic treatment of major depression for elderly patient in residential care
settings. Journal of Clinical Psychiatry, 51 (Suppl. 7), 41-7.
Katz, I.R., Jeste, D.V., Mintzer, J.E., Clyde, C., Napolitano, J., et al. for the Risperidone
Study Group. (1999). Comparison of risperidone and placebo for psychosis and
behavioral disturbances associated with dementia: a randomized, double-blind trial.
Journal of Clinical Psychiatry, 60, 107-15.
Koenig, H.G. and Breitner, J.C.S. (1990). Use of antidepressants in medically ill older
patients. Psychosomatics, 31, 22-31.
Kroessler, D. (1985). Relative efficacy rates for therapies of delusional depression.
Convulsive Therapy, 1, 173-82.
Laghrissi-Thode, F., Pollock, B.G., Miller, M., Altieri, L., and Kupfer, D.J. (1995).
Comparative effects of sertraline and nortriptyline on body sway in older depressed
patients. American Journal of Geriatric Psychiatry, 3, 217-28
Lantz, M.S. and Marin, D. (1996). Pharmacologic treatment of agitation in dementia: a
comprehensive review. Journal of Geriatric Psychiatry and Neurology, 9, 107-19.
Lawlor, B.A., Aisen, P.S., Green, C., Fine, E., and Schmeidler J. (1997). Selegiline in
the treatment of behavioral disturbance in Alzheirmers disease. International
Journal of Geriatric Psychiatry, 12, 319-22.
Lipsey, J.R., Robinson, R.G., Pearlson, G.D., Rao, K., and Price, T.R. (1984).
Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet, 1,
297-300.
Liu, B.A., Mittman, N., Knowles, S.R., and Shear, N.H. (1996). Hyponatremia and the
syndrome of inappropriate secretion of antidiuretic hormone associated with the use

of selective serotonin reuptake inhibitors: a review of spontaneous reports.

Canadian Medical Association Journal, 155, 519-27.
Liu, B., Anderson, G., Mittmann, N., To, T., Axcell, T., and Shear. (1998). Use of
selective serotonin reuptake inhibitors amd tricyclic antidepressants and risk of hip
fractures in elderly people. Lancet, 351, 1303-7.
Lovestone, S., Graham, N., amd Howard, R. (1997). Guidelines on drug treatments for
Alzheirmers disease. Lancet, 350, 232-3.
McKeith, I. and OBrien, J. (1999). Dementia with lewy bodies. Australian and New
Zealand Journal of Psychiatry, 33, 800-8.
McKeith, I.G., Grace, J.B., Walker, Z., Byrne, E.J., Wilkinson, D., Stevens, T. et al.
(2000). Rivastigmine in the treatment of dementia with Lewy bodies: preliminary
findings from an open trial. International Journal of Geriatric Psychiatry, 15, 38792.
Meara, R.J., Bhowmick, B.K., and Hobson, J.P. (1996). An open uncontrolled study of
the use of sertraline in the treatment of depression in Parkonsons disease. Journal
of Serotonin Research, 4, 243-9.
Meyers, B.S., Greenberg, R., and Mei-Tal, V. (1985). Delusional depression in the
elderly In treatment of affective disorders in the elderly (ed. C.A. Shamoian), pp.
19-28, American Psychiatric Press, Washington, DC.
Mulnard, R.A., Cotman, C.W., Kawas, C., van Dyck, C.H., Sano, M., Doody, R., et al.
(2000). Estrogen replacement therapy for treatment of mild to moderate Alzheirmer
disease: a randomized controlled trial. Alzheimers Disease Cooperative Study.
Journal of the American Medical Association, 283, 1007-15.
Nomeroff, C.B., DeVane, C.L. (1990). The clinical efficacy of citalopram in treatment
of emotional disturbances in dementia disorders. A Nordic multicenter study.
British journal of psychiatry, 157, 894-901.
Olafsson, K., Jorgensen, S., Jensen, H.V., Bille, A., Arup, P., and Andersen J. (1992).
Fluvoxamine in the treatment of demented elderly patients: a double-blind,
placebo-controlled study. Acta psychiatrica Scandinavica, 85, 453-6.
Parsa, M.A. and Bastani, B. (1998). Quetiapine (Seroquel) in the treatment of psychosis
in patients with Parkinsons disease. Journal of Neuropsychiatry and Clinical
Neurosciences, 10, 216-19.
Perry, P.J. (1996). Pharmacotherapy for major depression with melancholic features:
relative efficacy of tricyclic versus selective serotonin reuptake inhibitor
antidepressant. Journal of affective disorder, 39, 1-6.
Petracca, G., Teson, A., Chemerinski, E., Leiguarda, R., and Starkstein, SE. (1996). A
double-blind placebo-controlled study of clomiprapime in depressed patients with
Alzheimers disease. Journal of neuropsychiatry and clinical neurosciences, 8, 2705.

Petrie, W.M., Ban, T.A., Berney, S., Fujimori, M., Guy, W., Ragheb, M. et al. (1982).
Loxapine in psychogeriatrics: a placebo- and standard-controlled clinical
investigation. Journal of clinical psychopharmacology, 2, 122-6.
Pollock, B.G. and Mulsant, B.H. (1995). Antipsychotics in older patients. A safety
perspective. Drugs and Aging, 6, 312-23.
Pollock, B.G. and Mulsant, B.H. (1998). Behavioral disturbances of dementia. Journal
of Geriatric Psychiatry and Neurology, 11, 206-12.
Preskorn, S.H. (1993). Recent pharmacological advances in antidepressant therapy for
the elderly. American Journal of Medicine, 94 (Suppl. 5A), 2S 12S.
Preskorn, S. and Burke, M. (1992). Somatic therapy for major depressive disorder:
selection of an antidepressant. Journal of Clinical Psychiatry, 53(Suppl, 9), 5-18
Reynolds, C.F. 3rd, Frank, E., Perel, J.M., Miller, M.D., Paradis, C.F, Stack , J.A.,
et al. (1995). Nortriptyline side effects during double-blind, randomized, placebocontrolled maintenance therapy in older depressed patients. American Journal of
Geriatric Psychiatry, 3, 170-5.
Rickels, K. And Schweizer, E. (1990). Clinical overview of serotonin reuptake
inhibitors. Journal of Clinical Psychiatry, 51 (12, Suppl. B), 9-12.
Robinson, D.S., Roberts, D.L., Smith, J.M., Stringfellow, J.C., Kaplita , S.B., Seminara,
J.A., et al. (1996). The safety profile of nefazodone. Journal of Clinical Psychiatry,
57(Suppl.2), 31-8.
Rockwell, E., Lam, R.W., and Zisook, S. (1988). Antidepressant drug studies in the
elderly, Psychiatric Clinics of North America, 11, 215-33.
Rogers, J., Kirby, L.C., Hempelman, S.R., Berry, D.L., McGeer, P.L., Kazniak, A.W., et
al. (1993). Clinical trial of indomethacin in Alzheimers disease. Neurology, 43,
1609-11.
Rolan, P.E. (1994). Plasma protein binding displacement interactionsWhy are they
still regarded as clinically important? Briitish Journal of Clinical Pharmacology,
37, 125-8.
Roose, S.P. and Dalack, G.W. (1992). Treating the depressed patien with cardiovascular
problems. Journal of Clinical Psychiatry, 53(Suppl. 9), 25-31.
Roose, S.P., Laghrissi-Thode, F., Kennedy, J.S., Nelson, J.c, Bigger, J.T. Jr, pollock,
B.G., et al. (1998). Comparison of paroxetine and nortriptyline in depressed
patients with ischaemic heart disease. Journal of the American Medical
Association, 279,287-91.
Rosen, J., Sweet, R., Pollock, B.G., and Mulsant, B.H (1993). Nortriptyline in the
hospitalized elderly: tolerance and side effect reduction. Psychopharmarcology
Bulletin, 29, 327-31.

Roth, M., Mountjoy, C.Q., Amrein, R., and the International Collaborative Study Group
(1996). Moclobemide in elderly patients with cognitive decline and depression. An
international double-blind, placebo controlled study celecoxib in the treatment of
progression of Alzheimers disease. Sixth International Stockholm/Springfield
Symposium on Advances in Alzheimer Therapy Abstract Book, 180. Stockholm,
2000.
Sano, M., Ernesto, C., Thomas, R.G., Klauber, M.R., Schafer, k., Grundman, M., et al.
(1997). A controlled trial of seleginine, alpha-tocopherol, or both as treatment for
Alzheimers disease. New England Jornal of Medicine, 336, 1216-22.
Satel, S.L., and Nelson, J.C. (1989). Stimulants in the treatment of depression: a critical
overview. Journal of Clinical Psychiatry, 50, 241-9.
Schneider, L.S. (1996). Pharmacologic consideration in the treatment of latelifedepression. American Journal of Geriatric Psychiatry. 4(Suppl. 1), S51-S65.
Shader, R.I., von Moltke, L.L., Schneider, J.. Harmatz, J.S., and Greenbalt D.J. (1996).
The clinician and drug interactionsan update. Journal of Clinical
Psychopharmacology, 16, 197-201.
Shea, C., Macknight, C., Rockwood, K. (1998). Donezepil for treatment of dementia
with Lewy bodies: a case series in nine patients. International Psychogeriatrics, 10,
229-38.
Sheline, Y.I, Freedland, K.E, and Carney, R.M. (1997). Howw safe are serotonine
reuptake inhibitors for depression with coronary heart disease? American Journal
of Medicine, 102, 54-9.
Spiker, D.G., Weiss, J.C., Dealy, R.S., Griffin, S.J., Hanin, L., Neil, J.F., et al. (1985).
The pharmacological treatment of delusional depression. American Journal of
Psychiatry, 142, 430-6.
Sproule, B.A., Naranjo, C.A., Bremner, K.E., and Hasan, P.C. (1997). Selective
serotonine reuptake inhibitors and CNS drug interaction. A critical review of the
evidence, Clinical Pharmacokinetics, 33, 454-71.
Steinberg, J.R. (1994). Anxiety in elderly patients. A comparison of azapirones and
benzodiazepines. Drugs and Aging, 5, 335-45.
Sweet, R.A., and Pollock, B.G. (1998). New atypical antipsychotics. Experience and
utility in the elderly. Drugs and Aging, 12, 115-27.
Tariot, P.N., Erb, R., Podgorski, C.A, Cox, C., Patel, S., Jakimovich, L., et al. (1998a).
Efficacy and tolerability of carbamazepine for agitation and agression in dementia.
American Journal of Psychiatry, 155, 54-61.

Tariot, P.N., Goldstein, B., Podgorski, C.A, Cox, C., and Frambes, N. (1998b). Shortterm administration of selegiline for mild-to-moderate dementia of the Alzheimers
type. American Journal of Geriatric Psychiatry, 6, 145-54.
Taylor, D.P., Carter, R.B., Eison, A.S., Mullins, U.L., Smith, H.L., Torente, J.R., et al.
(1995). Pharmacology and neurochemistry of nefazodone, a novel antidepressant
drug. Journal of Clinical Psychiatry, 56(Suppl. 6), 3-11.
Thase, M.E., Rush, A.J., Kasper, S., and Nemeroff, C.B. (1994/995). Tricyclics and
newer antidepressant medication: treatment options for treatment-resistant
depression. Depression, 2, 152-68.
The parkinson Study Group. (1999). Low-dose of clozapine for the treatment of druginduced psychosis in Parkinsons disease. New England Journal of Medicine, 340,
757-63.
Thomas, D.R., Nelson, D.R., and Johnson, A.M. (1987). Biochemical effects of the
antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor.
Psychopharmacology (Berlin), 93, 193-200.
Tollefson, G.D., Beasley, C.M., Tamura, R.N., Tran, P.V., and Potvin, J.H. (1997).
Blind, controlled, long-term study of the comparative incidence of treatmentemergent tardive dyskinesia with olanzapine or haloperidol. American Journal of
Psychiatry, 154, 1248-54.
Wallace, A.E., Kofoed, L.L. and West, A.N. (1995). Double-blind, placebo-controlled
trial of methylphenidate in older, depressed medically ill patients. American
Journal of Psychiatry, 152, 929-31.
Wils, V., and Golke-Willemse, G. (1997). Extrapyramidal syndrome due to valproate
administration as an adjunt to lithium in an elderly manic patient. International
Journal of Geriatric Psychiatry, 12, 272.